Albiglutide vs Dulaglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicAlbiglutideDulaglutide
What it is

A GLP-1 receptor agonist fusion protein, in which GLP-1 analogue peptides are fused to human albumin, recorded by FDA’s substance registry as albiglutide.4

A GLP-1 receptor agonist. The label states that dulaglutide has 90% amino acid sequence similarity to human GLP-1.2

FDA status

FDA-approved

FDA-approved as Tanzeum; discontinued1

FDA-approved, but discontinued. Drugs@FDA lists Tanzeum, application 125431, with an original approval date of April 15, 2014, and lists it as discontinued.1

Is albiglutide FDA-approved?

FDA-approved

FDA-approved as Trulicity2,3

FDA-approved. Drugs@FDA lists Trulicity with an original approval date of September 18, 2014. The label carries a boxed warning about thyroid C-cell tumors in rats.2,3

Is dulaglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Albiglutide is not among them.5,6

Not among the six peptides the policy lists.5

FDA compounding safety-risk page

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list albiglutide.7

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial Harmony Outcomes (NCT02465515): a double-blind, randomized, placebo-controlled trial at 610 sites in 28 countries in 9,463 people with type 2 diabetes and cardiovascular disease, in which the composite of cardiovascular death, heart attack or stroke occurred in 7% on albiglutide and 9% on placebo.8

Large randomized human trials

  • Large randomized human trial REWIND (NCT01394952): a randomized, double-blind, placebo-controlled cardiovascular outcomes trial in 9,901 adults with type 2 diabetes and established cardiovascular disease or multiple risk factors, with a median follow-up of 5.4 years.2
  • Large randomized human trial A 26-week randomized, double-blind trial in 807 adults with type 2 diabetes that compared dulaglutide with metformin, one of several blood-sugar trials in the label.2
  • Controlled human trial A 26-week randomized, double-blind, placebo-controlled trial (NCT02963766) in 154 children aged 10 and older with type 2 diabetes.2
Records collected

13 ClinicalTrials.gov records and 4 PubMed records collected

11 ClinicalTrials.gov records and 38 PubMed records collected

Area of study

Metabolic and weight, Heart and blood vessels8

Metabolic and weight, Heart and blood vessels2

Latest dated events
  1. The Harmony Outcomes trial of albiglutide in 9,463 people is published.8
  2. FDA approves Tanzeum, application 125431, according to Drugs@FDA.1
  1. DailyMed publishes the Trulicity label version cited on this page.2
  2. FDA approves Trulicity, according to Drugs@FDA.3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  2. 2
    TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  3. 3
    Drugs@FDA application BLA125469 · original submission status AP · 2014-09-18 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Albiglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) · PMID 30291013 ↗

    The Lancet · Official source · Source checked November 16, 2026